{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:45:08Z","timestamp":1773211508027,"version":"3.50.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>To report a case of ribavirin-associated severe hyperuricemia in an immunocompromised patient treated for respiratory syncytial virus (RSV) infection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>A 21-year-old male with a past medical history of B-cell acute lymphoblastic leukemia was in full remission after allogenic bone marrow transplantation complicated with chronic graft-versus-host disease. He was hospitalized due to fever, malaise, and respiratory symptoms. A diagnosis of RSV upper respiratory tract infection complicated by secondary pneumonia was made, and oral ribavirin (600 mg in 3 divided doses daily) and intravenous levofloxacin (750 mg once daily) were initiated. On day 2 of the hospital admission, the patient\u2019s uric acid levels had increased from a baseline of 4 to 6 mg\/dL to 19.3 and 22.2 mg\/dL after the fourth and fifth doses of ribavirin, respectively, and his serum creatinine steadily had increased from a baseline of 0.7 to 0.8 mg\/dL to 1.6 mg\/dL. Ribavirin was discontinued after the sixth dose, and a single dose of intravenous rasburicase (7.5 mg) was administered. On day 3, the patient\u2019s serum uric and creatinine concentrations had decreased to 4.7 mg\/dL and 1.1 mg\/dL, respectively. He continued to recover on antibiotics and was discharged with normal uric acid and serum creatinine levels.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We report a case of severe hyperuricemia and acute kidney injury that developed early after initiation of ribavirin for RSV infection and suspected bacterial pneumonia in an immunocompromised patient without hepatitis C, requiring ribavirin discontinuation and rasburicase administration. To our knowledge, this is the first reported case of severe hyperuricemia in a patient treated with ribavirin for RSV infection rather than chronic hepatitis C. Clinicians should be aware of the possibility of acute and severe hyperuricemia following ribavirin administration.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxab043","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T17:08:49Z","timestamp":1614013729000},"page":"794-799","source":"Crossref","is-referenced-by-count":5,"title":["Acute and severe ribavirin-associated hyperuricemia and acute kidney injury: An underrecognized adverse effect"],"prefix":"10.1093","volume":"78","author":[{"given":"Razan","family":"Sakran","sequence":"first","affiliation":[{"name":"Section of Clinical Pharmacology and Toxicology, Rambam Health Care Campus, Haifa, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avraham","family":"Frisch","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rambam Health Care Campus, Haifa, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adi","family":"Elias","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rambam Health Care Campus, Haifa, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hend","family":"Sliman","sequence":"additional","affiliation":[{"name":"Medical Intensive Care Unit, Rambam Health Care Campus, Haifa, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Ammuri","sequence":"additional","affiliation":[{"name":"Medical Intensive Care Unit, Rambam Health Care Campus, Haifa, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Kurnik","sequence":"additional","affiliation":[{"name":"Section of Clinical Pharmacology and Toxicology, Rambam Health Care Campus, Haifa, Israel"},{"name":"Rappaport Faculty of Medicine, Technion \u2013 Israel Institute of Technology, Haifa, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"issue":"5","key":"2021042211435921900_CIT0001","first-page":"679","article-title":"Drug-induced hyperuricaemia and gout","volume":"56","author":"Ben Salem","year":"2017","journal-title":"Rheumatology (Oxford)."},{"issue":"1","key":"2021042211435921900_CIT0002","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4172\/jbb.1000173","article-title":"Effects on uric acid metabolism of the drugs except the antihyperuricemics","volume":"6","author":"Moriwaki","year":"2014","journal-title":"J Bioequivalence Bioavailab."},{"issue":"1","key":"2021042211435921900_CIT0003","first-page":"121","article-title":"Diuretic use, increased serum urate and the risk of incident gout in a population-based study of hypertensive adults: the Atherosclerosis Risk in Communities cohort study","volume":"64","author":"Gelber","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"4","key":"2021042211435921900_CIT0004","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1023\/A:1010789425975","article-title":"Uric acid nephrolithiasis associated with interferon and ribavirin treatment of hepatitis C","volume":"46","author":"Fontana","year":"2001","journal-title":"Dig Dis Sci."},{"issue":"1","key":"2021042211435921900_CIT0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1443-9573.2007.00316.x","article-title":"Investigation of hyperuricemia during pegylated-interferon-\u03b12b plus ribavirin combination therapy in patients with chronic hepatitis C","volume":"9","author":"Yamashita","year":"2008","journal-title":"J Dig Dis."},{"issue":"21","key":"2021042211435921900_CIT0006","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM199811193392102","article-title":"Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C","volume":"339","author":"Davis","year":"1998","journal-title":"N Engl J Med."},{"issue":"8","key":"2021042211435921900_CIT0007","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1046\/j.1365-2036.1998.00359.x","article-title":"Interferon alpha with ribavirin for the treatment of chronic hepatitis C in non-responders or relapses to interferon monotherapy","volume":"12","author":"Moreno-Monteagudo","year":"1998","journal-title":"Aliment Pharmacol Ther."},{"issue":"6","key":"2021042211435921900_CIT0008","first-page":"596","article-title":"Severe interferon\/ribavirin-induced hyperuricemia and urate nephropathy requiring rasburicase and hemodialysis in a liver transplant recipient","volume":"13","author":"Knorr","year":"2015","journal-title":"Exp Clin Transplant."},{"issue":"6","key":"2021042211435921900_CIT0009","first-page":"489","article-title":"Seguridad en la pr\u00e1ctica cl\u00ednica de la triple terapia con telaprevir en la hepatitis C cr\u00f3nica","volume":"37","author":"Sangrador Pelluz","year":"2013","journal-title":"Farm Hosp."},{"key":"2021042211435921900_CIT0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1023\/B:CARD.0000015855.02485.e3","article-title":"Cardiovascular drugs and serum uric acid","volume":"17","author":"Reyes","year":"2003","journal-title":"Cardiovasc Drugs Ther."},{"issue":"8","key":"2021042211435921900_CIT0011","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1097\/00004872-200018080-00021","article-title":"Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP)","volume":"18","author":"Franse","year":"2000","journal-title":"J Hypertens."},{"issue":"9","key":"2021042211435921900_CIT0012","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1524-6175.2004.03789.x","article-title":"Diuretic-related side effects: development and treatment","volume":"6","author":"Sica","year":"2004","journal-title":"J Clin Hypertens (Greenwich)."},{"issue":"3","key":"2021042211435921900_CIT0013","doi-asserted-by":"crossref","first-page":"E347","DOI":"10.1111\/hepr.12971","article-title":"Elevated serum uric acid level was a notable adverse event during combination therapy with sofosbuvir and ribavirin","volume":"48","author":"Sato","year":"2018","journal-title":"Hepatol Res."},{"issue":"2","key":"2021042211435921900_CIT0014","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/hepr.12914","article-title":"Efficacy and safety of telaprevir with natural human interferon-\u03b2 and ribavirin in Japanese chronic hepatitis C patients with depression","volume":"48","author":"Kumada","year":"2018","journal-title":"Hepatol Res."},{"issue":"2","key":"2021042211435921900_CIT0015","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther."},{"issue":"6","key":"2021042211435921900_CIT0016","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0272-6386(98)70067-8","article-title":"Regulation of renal urate excretion: a critical review","volume":"32","author":"Maesaka","year":"1998","journal-title":"Am J Kidney Dis."},{"issue":"9138","key":"2021042211435921900_CIT0017","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of interferon \u03b12b plus ribavirin for 48 weeks or for 24 weeks versus interferon \u03b12b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet."},{"issue":"1","key":"2021042211435921900_CIT0018","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/jac\/dki405","article-title":"Treating HCV with ribavirin analogues and ribavirin-like molecules","volume":"57","author":"Gish","year":"2006","journal-title":"J Antimicrob Chemother."},{"issue":"4","key":"2021042211435921900_CIT0019","doi-asserted-by":"crossref","first-page":"A1445","DOI":"10.1016\/S0016-5085(00)81674-1","article-title":"Hyperuricemia associated with ribavirin treatment of chronic hepatitis C indicating IMPDH inhibition: a possible mode of antiviral activity?","volume":"118","author":"Halai","year":"2000","journal-title":"Gastroenterology."},{"issue":"1","key":"2021042211435921900_CIT0020","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.transproceed.2016.11.015","article-title":"Hyperuricemia and acute renal failure in renal transplant recipients treated with high-dose mizoribine","volume":"49","author":"Akioka","year":"2017","journal-title":"Transplant Proc."},{"issue":"3","key":"2021042211435921900_CIT0021","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.transproceed.2015.12.117","article-title":"Efficacy and safety of high-dose mizoribine combined with cyclosporine, basiliximab, and corticosteroids in renal transplantation: a Japanese multicenter study","volume":"48","author":"Ushigome","year":"2016","journal-title":"Transplant Proc."},{"issue":"1","key":"2021042211435921900_CIT0022","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1523-1755.2000.00168.x","article-title":"A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome","volume":"58","author":"Yoshioka","year":"2000","journal-title":"Kidney Int."},{"key":"2021042211435921900_CIT0023","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1749-6632.1993.tb35869.x","article-title":"IMP dehydrogenase Inhibitors as Immunomodulators","volume":"685","author":"Mitchell","year":"1993","journal-title":"Ann N Y Acad Sci."},{"key":"2021042211435921900_CIT0024","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.biopha.2014.10.030","article-title":"Role of pharmacogenetics in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients","volume":"69","author":"Allegra","year":"2015","journal-title":"Biomed Pharmacother."},{"key":"2021042211435921900_CIT0025","doi-asserted-by":"crossref","first-page":"109657","DOI":"10.1016\/j.biopha.2019.109657","article-title":"The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir\/daclatasvir and ribavirin","volume":"121","author":"Abdelkawy","year":"2020","journal-title":"Biomed Pharmacother."},{"issue":"7","key":"2021042211435921900_CIT0026","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1111\/j.1476-5381.2010.00987.x","article-title":"Pharmacogenetics of the mycophenolic acid targets inosine monophosphate dehydrogenases IMPDH1 and IMPDH2: gene sequence variation and functional genomics","volume":"161","author":"Wu","year":"2010","journal-title":"Br J Pharmacol."},{"issue":"9","key":"2021042211435921900_CIT0027","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1097\/00006454-199009001-00009","article-title":"Ribavirin pharmacokinetics","volume":"9","author":"Connor","year":"1990","journal-title":"Pediatr Infect Dis J."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxab043\/36335895\/zxab043.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/78\/9\/794\/37257070\/zxab043.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/78\/9\/794\/37257070\/zxab043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T22:11:21Z","timestamp":1619129481000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/78\/9\/794\/6146533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,22]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,2,22]]},"published-print":{"date-parts":[[2021,4,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxab043","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2021,2,22]]}}}